Celltrion announced it will burn approximately 100 billion won worth of its own shares. This brings the total value of share buybacks for the year to 200 billion won.
On September 16, Celltrion stated that it has resolved to burn 540,299 shares, valued at about 100 billion won, to enhance shareholder value. The share cancellation is scheduled for September 30, with the listing of the changes expected to be completed in October. With this resolution, the total value of shares that Celltrion plans to acquire and burn this year will increase to approximately 200 billion won.
This share cancellation is part of Celltrion's long-term principle of returning one-third (about 33%) of its annual consolidated net profit to shareholders through share buybacks or cash dividends.
Celltrion explained, "This share buyback and subsequent cancellation is a measure to eliminate any possibility of reissuing the shares recently acquired. By completing both the acquisition and cancellation of shares, we aim to enhance the certainty of shareholder returns and improve market predictability regarding our policies."
Previously, Celltrion announced its long-term principle of returning one-third of its annual consolidated net profit to shareholders. The company plans to review various factors, including stock valuation, market conditions, free cash flow, research and development (R&D), and global facility investment plans, to determine the allocation between cash dividends and share buybacks or cancellations each year. If the stock is deemed undervalued compared to the company's intrinsic value or growth potential, Celltrion intends to actively utilize its share buyback policy, while also providing cash dividends when necessary to enhance return effects.
Celltrion expects that as its existing core products, including biosimilars Remsima, Truxima, and Herzuma, maintain their market positions, the expansion of prescriptions for next-generation high-revenue portfolios such as Uplizna, Vegzelma, and Omniclon will further strengthen its long-term performance momentum.
Based on this, Celltrion aims to balance future growth investments and shareholder returns, creating a virtuous cycle that enhances both corporate and shareholder value. A Celltrion representative stated, "We will consistently implement the principle of returning one-third of our consolidated net profit to shareholders to build market trust."
Meanwhile, Celltrion achieved record-high consolidated revenues of 4.1625 trillion won and operating profits of 1.1685 trillion won last year. In the first half of this year, the company reported revenues of 2.5387 trillion won and operating profits of 773.7 billion won, continuing its trend of growth and improved profitability.
On September 16, Celltrion stated that it has resolved to burn 540,299 shares, valued at about 100 billion won, to enhance shareholder value. The share cancellation is scheduled for September 30, with the listing of the changes expected to be completed in October. With this resolution, the total value of shares that Celltrion plans to acquire and burn this year will increase to approximately 200 billion won.
This share cancellation is part of Celltrion's long-term principle of returning one-third (about 33%) of its annual consolidated net profit to shareholders through share buybacks or cash dividends.
Celltrion explained, "This share buyback and subsequent cancellation is a measure to eliminate any possibility of reissuing the shares recently acquired. By completing both the acquisition and cancellation of shares, we aim to enhance the certainty of shareholder returns and improve market predictability regarding our policies."
Previously, Celltrion announced its long-term principle of returning one-third of its annual consolidated net profit to shareholders. The company plans to review various factors, including stock valuation, market conditions, free cash flow, research and development (R&D), and global facility investment plans, to determine the allocation between cash dividends and share buybacks or cancellations each year. If the stock is deemed undervalued compared to the company's intrinsic value or growth potential, Celltrion intends to actively utilize its share buyback policy, while also providing cash dividends when necessary to enhance return effects.
Celltrion expects that as its existing core products, including biosimilars Remsima, Truxima, and Herzuma, maintain their market positions, the expansion of prescriptions for next-generation high-revenue portfolios such as Uplizna, Vegzelma, and Omniclon will further strengthen its long-term performance momentum.
Based on this, Celltrion aims to balance future growth investments and shareholder returns, creating a virtuous cycle that enhances both corporate and shareholder value. A Celltrion representative stated, "We will consistently implement the principle of returning one-third of our consolidated net profit to shareholders to build market trust."
Meanwhile, Celltrion achieved record-high consolidated revenues of 4.1625 trillion won and operating profits of 1.1685 trillion won last year. In the first half of this year, the company reported revenues of 2.5387 trillion won and operating profits of 773.7 billion won, continuing its trend of growth and improved profitability.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.